Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post-Randomization Analysis.

ABSTRACT:

Background

A low serum testosterone can prolong the time needed for PSA to exceed normal and prompt a work-up to rule out prostate cancer (PC), delaying diagnosis. We evaluated PC aggressiveness at diagnosis and PC-specific and all-cause mortality (PCSM, ACM)-risk within comorbidity subgroups in patients with low versus normal testosterone.

Methods

Between 2005 and 2015, 350 PSA-screened patients with tumor (T) category1c-4N0M0 unfavorable-risk PC were enrolled in a randomized trial and comprised the study cohort. Fine and Gray and Cox multivariable regression analyses were used to evaluate PCSM and ACM risk, respectively, adjusting for age, known PC prognostic factors, randomized treatment arm, and the time-dependent use of salvage androgen deprivation therapy. An interacti

SUBMITTER: Fattahi S 

PROVIDER: S-EPMC12314635 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature